Background
Methods
Eligibility criteria
Search strategy
Study selection, data extraction and quality assessment
Data synthesis
Changes to protocol
Results
First author Year Country | Model Type | HCV population | Regimens evaluateda | Perspective | Time horizon Discount rate Cycle length | Sponsor | Included in analysis, Y/N |
---|---|---|---|---|---|---|---|
Athanasakis 2015 Greece | Markov | Tx naïve & Tx experienced, G1 | TT (BOC-PEG-RBV), DT (PEG-RBV) | 3rd party payer | Lifetime 3%a 1 wk | Merck Sharp & Dohme Corp. | N |
Blazquez-Perez 2013 Spain | Markov | Tx naïve, G1 | TT (BOC-PEG-RBV, TEL-PEG-RBV), DT (PEG-RBV) | Spanish NHS | Lifetime 3% 3 mthsa | Unsupportedb | N |
Brogan 2014 USA | Markov | Tx naïve & Tx experienced, G1 | TT (TEL-PEG-RBV), DT (PEG-RBV) | US payer perspective | Lifetime 3%a 1 yr | Vertex Pharmaceuticals Incorporated | N |
Camma 2013 Italy | Semi Markov | Tx experienced, G1, Aged 50+ | TT (BOC/TEL-PEG-RBV), No Tx | Italian NHS | Lifetime 3%a 1 yr | 3P Solution | N |
Camma 2012 Italy | Semi Markov | Tx naïve, G1, Aged 50+ | TT (BOC/TEL-PEG-RBV), DT (PEG-RBV) | Italian NHSc | 20-yr 3%a 1 yr | 3P Solution | N |
Chan 2013 USA | Markov | Tx naïve, G1 | TT (BOC-PEG-RBV, TEL-PEG-RBV), DT (PEG-RBV), No Tx | VHA Healthcare Organization | Lifetime 3%a 1 yr | Dept. Of Veteran Affairs Health Services Research and DQERI | N |
Chhatwal 2015 USA | Markov (Individual) | Tx naïve & Tx experienced, G1–4 | TT (SOF-PEG-RBV, BOC-PEG-RBV, TEL-PEG-RBV), DT (SOF-LDV, SOF-RBV, PEG-RBV) | Third party payer | Lifetime 3%a 1 wk | NIH (award #KL2TR000146) | N |
Chhatwal 2013 USA | Markov | Tx experienced, G1 | TT (BOC-PEG-RBV), DT (PEG-RBV) | Payer | Lifetime 3%a 1 wk | Merck Sharp & Dohme Corp. (in part) | N |
Cortesi 2015 USA | Semi Markov | Tx naïve, G1 | TT (BOC-PEG-RBV, TEL-PEG-RBV) | Italian NHS | Lifetime 3%a 1 yr | Unsupported | N |
Cure 2015a Italy | Markov | Tx naïve & Tx experienced, G1–6 | DT (PEG-RBV, SOF-RBV), TT (SOF-PEG-RBV, TEL-PEG-RBV, BOC-PEG-RBV), No Tx | Italian NHS | Lifetime 3%a 3 mths & 1 yrd | Gilead Sciences | Y |
Cure 2015b UK | Markov | Tx naïve & Tx experienced, G1–6 | TT (SOF-PEG-RBV, BOC-PEG-RBV, TEL-PEG-RBV), DT (SOF-RBV, PEG-RBV), No Tx | UK NHS perspective | Lifetime 3.5%a 3 mths & 1 yrd | Gilead Sciences | Y |
Cure 2014a UK | Markov | Tx naïve, G1 | TT (BOC-PEG-RBV, TEL-PEG-RBV) | UK NHS | Lifetime 3.5%a 1 yr | Janssen Pharmaceuticals | N |
Cure 2014b UK | Markov | Tx experienced, G1 | TT (BOC-PEG-RBV, TEL-PEG-RBV) | Italian NHS | Lifetime 3.5%a 1 yr | Janssen Pharmaceuticals | N |
Dan 2015 Singapore | Markov | Tx naïve & Tx experienced, G1 | TT (BOC-PEG-RBV), DT (PEG-RBV) | Public | Lifetime 3%a 1 yr | Merck & Co Inc. & MSD Pharma (Singapore) Pte. Ltd. | N |
Elbasha 2013 Portugal | Markov | Tx naïve & Tx experienced, G1 | TT (BOC-PEG-RBV), DT (PEG-RBV) | Portuguese NHS | Lifetime 5%a 1 wk | Merck Sharp & Dohme Corp. | N |
Ferrante 2013 USA | Markov | Tx naïve, G1 | TT (BOC-PEG-RBV), DT (PEG-RBV) | Payer | Lifetime 3%a 1 wk | Schering Plough (part of Merck Sharp & Dohme Corp.) | N |
Gimeno-Ballester 2016 Spain | Markov | Tx naïve, G1b | DT (SMV, DCV), TT (BOC-PEG-RBV, TEL-PEG-RBV) | Spanish NHS | Lifetime 3%a 3 mths | Unsupported | N |
Hagan 2014 USA | Markov | Tx naïve & Tx experienced | DT (SOF-SMV, SOF-RBV) | Societal | Lifetime 3%a 1 yr | Grants from NIH and Department of Veterans Affairs | N |
Leleu 2015 France | Markov | Tx naïve & Tx experienced, G1–4 | TT (SOF-PEG-RBV, TEL-PEG-RBV), DT (PEG-RBV) | French NHS | Lifetime 2.5%a 3 mths, 1 yr | Gilead Sciences | N [no usable data] |
Linas 2015 USA | Monte Carlo Simulation | Tx naïve & Tx experienced, G2–3 | TT (SOF-PEG-RBV), DT (SOF-RBV, PEG-RBV), No Tx | Payer | Lifetime 3%a 1 mth | NIDA & NIAID | Y |
Linas 2014 USA | Monte Carlo Simulation | HIV/HCV co-infected (Tx naïve, G1, non-cirrhotic) | TT (TEL-PEG-RBV), DT (PEG-RBV), No Tx | Health system | Lifetime 3%a 1 mth | NIDA & NIAID | N |
Liu 2014 USA | Markov | Tx naïve men, G1, Age 40+ | TT (SOF-PEG-RV, BOC-PEG-RBV), DT (PEG-RBV), No Tx | Societal | Lifetime 3%a 3 mths | US Dept. for Veteran Affairs, NIA, and NIH | Y |
Liu 2012 USA | Markov | Tx naïve, G1 | TT (BOC/TEL-PEG-RBV), DT (PEG-RBV) | Societal | Lifetime 3%a 1 yr | Stanford Graduate Fellowship | N |
McEwan 2014 Japan | Markov | Tx naïve & Tx experienced, G1b | TT (TEL-PEG-RBV) DT (DCV-ASV, PEG-RBV), No Tx | Japanese health system | Lifetime 2%a 1 yr | Bristol-Myers Squibb | N |
Najafzadeh 2015 USA | Discrete Event Simulation | Tx naïve, G1–3 | TT (BOC-PEG-RBV, SOF-PEG-RBV, SOF-LED-RBV), DT (SOF-SIM, SOF-DCV, SOF-LED, SOF-RBV, PEG-RBV) | Societal | Lifetime 3%a NA | CVS Health | Y |
Petta 2014a Italy | Semi Markov | Tx naïve, G1, Age 50+ | TT (SOF-PEG-RBV, BOC-PEG-RBV, TEL-PEG-RBV) | Italian National Health Service | Lifetime 3%a 1 yr | 3P Solution | N |
Petta 2014b Italy | Semi Markov | Tx naïve, G1, Age 50+ | TT (BOC-PEG-RBV), DT (PEG-RBV) | Italian National Health Service | Lifetime 3%a 1 yr | Not reported | N |
Pfeil 2015 Switzerland | Markov | Tx naïve & Tx experienced G1–4 | TT (SOF-PEG-RBV, TEL-PEG-RBV, BOC-PEG-RBV), DT (PEG-RBV, SOF-RBV), No Tx | Swiss NHS | Lifetime 3%a 1 yr | Gilead Switzerland | Y |
Rein 2015 USA | Markov | Tx naïve, G1–4 | DT (PEG-RBV, SOF-RBV, SIM-SOF), TT (SOF-PEG-RBV), No Tx | Healthcare | Lifetime 3%a 1 yr | National Foundation for CDC & Prevention | N |
Saab 2014 USA | Markov | Tx naïve, Tx experienced & Tx naïve with HIV coinfection | TT (SOF-PEG-RBV, BOC-PEG-RBV, TEL-PEG-RBV, SIM-PEG-RBV), DT (PEG-RBV) | 3rd party payer | Lifetime 3%a 1 yr | Gilead Sciences Inc. | Y |
San Miguel 2014 Spain | Markov | Tx naïve & Tx experienced, G1–3 | TT (SOF-PEG-RBV, BOC-PEG-RBV, TEL-PEG-RBV), DT (PEG-RBV, SOF-RBV) | Spanish NHS | Lifetime 3%a 3 mths | Not reportede | Y |
Tice 2015 USA | Markov | Tx naïve & Tx experienced, G1–3, Age 60+ | TT (SOF-PEG-RBV, TEL-PEG-RBV, SMV-PEG-RBV, SOF-SMV-RBV), DT SOF-RBV), No Tx | US 3rd party payer | Lifetime 3%a 1 yr | ICER & CTAF | N |
Vellopoulou 2014 The Netherlands | Markov | Tx naïve & Tx experienced, G1 | TT (SOF-PEG-RBV, BOC.PEG-RBV), DT (PEG-RBV) | Societal | Lifetime 4% costs; 1% outcomes 1 yr | Janssen-Cilag B.V. | N |
Warren 2014 Australia | Markov | Tx naïve & Tx experienced, G1 | TT (TEL-PEG-RBV), DT (PEG-RBV) | Lifetime 5%a 1 yr | Janssen Australia Pty Ltd | N | |
Westerhout 2015 UK | Markov | Tx naïve & Tx experienced, G1, Age 50+ | TT (SMV-PEG-RBV, TEL-PEG-RBV, BOC-PEG-RBV), DT (PEG-RBV) | UK NHS | Lifetime 3.5%a 1 yr | Janssen EMEA | N |
Younossi 2015 USA | Markov | Tx naïve & Tx experienced, G1 | DT (SOF-LDV, SOF-SMV, SOF-RBV), TT (SOF-PEG-RBV, SMV-PEG-RBV, BOC-PEG-RBV), No Tx | US 3rd party payer | Lifetime 3%a 1 yr | Gilead Sciences Inc. | N |
Zhang 2015 USA | Markov (patient) | Tx naïve, G1–3 | DT (PEG-RBV, SOF-RBV, LED-SOF, SIM-SOF), TT (SOF-PEG-RBV), ViekiraPak (OMB-PAR-RIT-DAS) | Unclear | Lifetime 3%a 1 yr | National Science Foundation (grant #IIP-1361509 & #DGE1255832) | N |
First author Year Country | Model Type | HCV population | Regimens evaluateda | Perspective | Time horizon Discount rate Cycle length | Sponsor |
---|---|---|---|---|---|---|
Canavan 2013 [56] UK | Markov | Newly diagnosed with chronic HCV and no fibrosis | • Intermittent biopsy followed by ultrasound and blood test every 6 mths • Annual biopsy followed by liver cancer screening at 6-mth intervals once cirrhosis identified • Replacing intermittent liver biopsy by TE with confirmation liver biopsy, followed by liver cancer screening at 6-month intervals once cirrhosis identified • Annual TE with confirmation liver biopsy, followed by liver cancer screening at 6-mth intervals once cirrhosis identified • Annual TE as a definitive test, followed by liver cancer screening at 6-mth intervals once cirrhosis identified • No surveillance of fibrosis stage | UK NHS (Hospital) | Lifetime 3.5%a 3 mths | Lead author funded by MRC Population Health Science Fellowship |
Crossanb 2015 [54] UK | Markov | HBV, HCV (G1–4, with suspected fibrosis, who usually present for liver biopsy), ALD, NAFLDc | • TE • FibroTest • ARFI • Other invasive tests (including: DwMRI, • FibroIndex, contract-enhanced ultrasound, and Type IV collagen) • Liver biopsy | UK NHS | Lifetime 3.5%a 3 mths | UK NIHR HTA Programme |
Liu 2011 [57] USA | Markov | Tx naïve, G1–3 | • FibroTest • FibroTest & liver biopsy • FibroTest rule-in • FibroTest rule-out • Liver biopsy only (recommended practice) • Immediate Tx | Payer | Lifetime 3%a 6 mths | US NIH NIA Career development & Stanford Graduate Fellowship |
Model characteristics
Therapeutic intervention
Model type and structure
HCV population
Perspective and sponsor
Regimens
n | Genotype 1 n (%) | Genotype 2 n (%) | Genotype 3 n (%) | ||
---|---|---|---|---|---|
Prior treatment status | Treatment Experienced | 47 | 15 (30.61) | 9 (34.62) | 23 (45.1) |
Treatment Naïve | 79 | 34 (69.39) | 17 (65.38) | 28 (54.9) | |
Population | All Patients | 61 | 27 (55.1) | 13 (50) | 21 (41.18) |
With Cirrhosis | 39 | 14 (28.57) | 8 (30.77) | 17 (33.33) | |
Without Cirrhosis | 26 | 8 (16.33) | 5 (19.23) | 13 (25.49) | |
Articles | Linas, 2015 | 20 | 0 (0) | 6 (23.08) | 14 (27.45) |
Liu, 2014 | 1 | 1 (2.04) | 0 (0) | 0 (0) | |
Najafzadeh, 2015 | 3 | 1 (2.04) | 1 (3.85) | 1 (1.96) | |
Saab, 2014 | 16 | 16 (32.65) | 0 (0) | 0 (0) | |
SanMiguel, 2014 | 8 | 2 (4.08) | 2 (7.69) | 4 (7.84) | |
Cure, 2015 (Italy) | 31 | 14 (28.57) | 8 (30.77) | 9 (17.65) | |
Cure, 2015 (UK) | 13 | 4 (8.16) | 4 (15.38) | 5 (9.8) | |
Pfeil, 2015 | 34 | 11 (22.45) | 5 (19.23) | 18 (35.29) | |
Treatments | SOF PEG RBV 12 wk. vs BOC PEG RBV 48 wk | 14 | 14 (28.57) | 0 (0) | 0 (0) |
SOF PEG RBV 12 wk. vs No Tx | 7 | 4 (8.16) | 0 (0) | 3 (5.88) | |
SOF PEG RBV 12 wk. vs PEG RBV 24 wk | 11 | 0 (0) | 2 (7.69) | 9 (17.65) | |
SOF PEG RBV 12 wk. vs PEG RBV 48 wk | 19 | 13 (26.53) | 0 (0) | 6 (11.76) | |
SOF PEG RBV 12 wk. vs TEL PEG RBV 48 wk | 11 | 11 (22.45) | 0 (0) | 0 (0) | |
SOF RBV 12 wk. vs No Tx | 16 | 0 (0) | 12 (46.15) | 4 (7.84) | |
SOF RBV 12 wk. vs PEG RBV 24 wk | 10 | 0 (0) | 8 (30.77) | 2 (3.92) | |
SOF RBV 12 wk. vs PEG RBV 48 wk | 4 | 0 (0) | 4 (15.38) | 0 (0) | |
SOF RBV 24 wk. vs No Tx | 22 | 6 (12.24) | 0 (0) | 16 (31.37) | |
SOF RBV 24 wk. vs PEG RBV 24 wk | 7 | 0 (0) | 0 (0) | 7 (13.73) | |
SOF RBV 24 wk. vs PEG RBV 48 wk | 5 | 1 (2.04) | 0 (0) | 4 (7.84) | |
Total | 126 | 49 (38.89) | 26 (20.63) | 51 (40.48) |
Surveillance
Model type and structure
HCV population
Perspective and sponsor
Regimens
Quality appraisal
Therapeutic intervention
Intervention | Surveillance | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Philips criteriaa | Cure, 2015a [28] | Cure, 2015b [28] | Linas, 2015 [37] | Liu, 2014 [39] | Najfzadeh, 2015 | Pfeil, 2015 [44] | Saab, 2014 [46] | San Miguel, 2015 [47] | Canavan, 2013 [56] | Crossan, 2015b | Liu, 2011 [57] |
S1 | Unclear | Yes | Yes | Yes | Yes | Yes | Yes | Unclear | Yes | Yes | Yes |
S2 | Unclear | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
S3 | Yes | Yes | Unclear | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
S4 | No | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
S5 | Unclear | Yes | Yes | Yes | Yes | Yes | Yes | Unclear | Yes | Yes | Yes |
S6 | Unclear | Yes | Unclear | Yes | Yes | Yes | Yes | Unclear | Yes | Yes | Yes |
S7 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
S8 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
S9 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
D1 | No | Unclear | Unclear | Yes | Unclear | Unclear | Unclear | No | Yes | Yes | Yes |
D2 | Unclear | Unclear | Unclear | No | Unclear | Unclear | No | No | Yes | Unclear | Yes |
D2A
| Yes | Yes | Unclear | Unclear | Yes | Yes | No | No | Yes | Yes | Yes |
D2B
| Unclear | Unclear | Unclear | Yes | Unclear | Unclear | Yes | No | Yes | Yes | Yes |
D2C
| Yes | Yes | Unclear | No | Yes | Yes | Unclear | No | Yes | Yes | Yes |
D3 | Unclear | No | Unclear | Yes | Yes | Yes | Yes | No | Yes | Yes | Yes |
D4 | Yes | No | No | Yes | Yes | Yes | No | No | Yes | Yes | Yes |
D4A
| Yes | No | Yes | Yes | Yes | Yes | Unclear | No | Yes | Yes | Yes |
D4B
| Yes | Unclear | Yes | Yes | Yes | Yes | Unclear | No | Yes | Yes | Yes |
D4C
| Yes | Yes | Yes | No | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
D4D
| Yes | Yes | Unclear | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
C1 | No | Yes | No | Yes | Yes | Yes | Unclear | No | Yes | Yes | Yes |
C2 | No | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
Intervention | Surveillance | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
CHEERS criteriaa | Cure, 2015a [28] | Cure, 2015b [28] | Linas, 2015 [37] | Liu, 2014 [39] | Najfzadeh, 2015 | Pfeil, 2015 [44] | Saab, 2014 [46] | San Miguel, 2015 [47] | Canavan, 2013 [56] | Crossan, 2015b [54] | Liu, 2011 [57] |
Q1 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
Q2 | Unclear | Yes | Yes | Yes | Yes | Yes | Yes | Unclear | Yes | Yes | Yes |
Q3 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
Q4 | Yes | Yes | Yes | No | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
Q5 | Yes | Yes | Unclear | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
Q6 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
Q7 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
Q8 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
Q9 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
Q10 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
Q11a | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
Q11b | No | Unclear | Unclear | Yes | Unclear | Unclear | Unclear | Yes | Unclear | Yes | Unclear |
Q12 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
Q13a | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
Q13b | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
Q14 | No | Yes | Yes | Yes | Yes | Yes | Yes | Unclear | Yes | Yes | Yes |
Q15 | Yes | Yes | Unclear | Unclear | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
Q16 | Unclear | Unclear | Unclear | Yes | Yes | Unclear | Unclear | Unclear | Yes | Yes | Yes |
Q17 | Unclear | Unclear | Unclear | Unclear | Unclear | Unclear | Unclear | Unclear | Yes | Yes | Yes |
Q18 | No | Unclear | Yes | Unclear | Yes | Yes | No | Yes | Yes | Yes | Yes |
Q19 | No | Yes | Yes | No | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
Q20 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
Q21 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
Q22 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
Q23 | Yes | Yes | Yes | Yes | No | Yes | Unclear | Yes | Yes | Yes | Yes |
Q24 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
Surveillance
Synthesis results
Therapeutic intervention
Genotype | Response | Population | Treatment | n | Mean | 95% CI |
---|---|---|---|---|---|---|
1 | Tx Naïve | All Patients | SOF PEG RBV 12 wk. vs BOC PEG RBV 48 wk | 5 | $18,499.62 | 6871.38; 30,127.86 |
1 | Tx Naïve | All Patients | SOF PEG RBV 12 wk. vs PEG RBV 48 wk | 5 | $26,460.59 | 18,342.69; 34,578.49 |
2 | Tx Naïve | All Patients | SOF RBV 12 wk. vs PEG RBV 24 wk | 5 | $88,099.60 | 68,301.59; 107,897.61 |
3 | Tx Naïve | All Patients | SOF PEG RBV 12 wk. vs PEG RBV 24 wk | 4 | $41,080.16 | 28,962.61; 53,197.71 |
3 | Tx Experienced | All Patients | SOF PEG RBV 12 wk. vs PEG RBV 48 wk | 4 | $29,092.09 | 9276.64; 48,907.54 |
1 | Tx Naïve | All Patients | SOF PEG RBV 12 wk. vs TEL PEG RBV 48 wk | 3 | $25,954.71 | − 242.37; 52,151.79 |
1 | Tx Naïve | All Patients | SOF RBV 24 wk. vs No Tx | 3 | $61,607.34 | 43,706.46; 79,508.22 |
2 | Tx Naïve | All Patients | SOF RBV 12 wk. vs No Tx | 3 | $13,411.94 | 6648.19; 20,175.69 |
2 | Tx Experienced | All Patients | SOF RBV 12 wk. vs PEG RBV 48 wk | 3 | $38,521.07 | 8866.40; 68,175.74 |
3 | Tx Naïve | With Cirrhosis | SOF PEG RBV 12 wk. vs PEG RBV 24 wk | 3 | $15,496.88 | 5997.08; 24,996.68 |
3 | Tx Experienced | All Patients | SOF RBV 24 wk. vs No Tx | 3 | $34,349.09 | 23,903.12; 44,795.06 |
3 | Tx Experienced | With Cirrhosis | SOF RBV 24 wk. vs No Tx | 3 | $61,199.47 | −11,419.99; 133,818.93 |
3 | Tx Naïve | All Patients | SOF RBV 24 wk. vs No Tx | 3 | $26,708.10 | 20,272.80; 33,143.40 |
3 | Tx Naïve | With Cirrhosis | SOF RBV 24 wk. vs No Tx | 3 | $16,688.78 | 5501.36; 27,876.20 |
1 | Tx Experienced | With Cirrhosis | SOF PEG RBV 12 wk. vs BOC PEG RBV 48 wk | 2 | $8155.21 | − 6369.20; 22,679.62 |
1 | Tx Naïve | With Cirrhosis | SOF PEG RBV 12 wk. vs BOC PEG RBV 48 wk | 2 | $14,343.01 | 2811.59; 25,874.43 |
1 | Tx Experienced | All Patients | SOF PEG RBV 12 wk. vs PEG RBV 48 wk | 2 | $16,338.76 | − 9294.13; 41,971.65 |
1 | Tx Experienced | With Cirrhosis | SOF PEG RBV 12 wk. vs PEG RBV 48 wk | 2 | $9308.71 | − 6564.02; 25,181.44 |
1 | Tx Naïve | With Cirrhosis | SOF PEG RBV 12 wk. vs PEG RBV 48 wk | 2 | $14,480.59 | 10,944.65; 18,016.53 |
1 | Tx Naïve | With Cirrhosis | SOF RBV 24 wk. vs No Tx | 2 | $45,242.13 | 19,014.80; 71,469.46 |
2 | Tx Experienced | All Patients | SOF RBV 12 wk. vs No Tx | 2 | $16,839.10 | 13,661.57; 20,016.63 |
2 | Tx Experienced | With Cirrhosis | SOF RBV 12 wk. vs No Tx | 2 | $20,559.84 | 5250.75; 35,868.93 |
2 | Tx Naïve | With Cirrhosis | SOF RBV 12 wk. vs No Tx | 2 | $12,953.61 | 3499.67; 22,407.55 |
2 | Tx Naïve | Without Cirrhosis | SOF RBV 12 wk. vs No Tx | 2 | $31,518.88 | − 3263.39; 66,301.15 |
2 | Tx Naïve | With Cirrhosis | SOF RBV 12 wk. vs PEG RBV 24 wk | 2 | $33,523.44 | 21,330.96; 45,715.92 |
3 | Tx Experienced | All Patients | SOF PEG RBV 12 wk. vs No Tx | 2 | $16,543.85 | 9323.35; 23,764.35 |
3 | Tx Naïve | Without Cirrhosis | SOF PEG RBV 12 wk. vs PEG RBV 24 wk | 2 | $162,539.68 | −43,346.34; 368,425.70 |
3 | Tx Experienced | Without Cirrhosis | SOF RBV 24 wk. vs No Tx | 2 | $87,973.28 | − 4537.35; 180,483.91 |
3 | Tx Naïve | Without Cirrhosis | SOF RBV 24 wk. vs No Tx | 2 | $52,992.71 | 20,221.61; 85,763.81 |
3 | Tx Naïve | All Patients | SOF RBV 24 wk. vs PEG RBV 24 wk | 2 | $97,028.01 | 45,661.88; 148,394.14 |
3 | Tx Naïve | With Cirrhosis | SOF RBV 24 wk. vs PEG RBV 24 wk | 2 | $28,155.70 | 15,997.15; 40,314.25 |
3 | Tx Naïve | Without Cirrhosis | SOF RBV 24 wk. vs PEG RBV 24 wk | 2 | $200,289.75 | 94,317.94; 306,261.56 |
3 | Tx Experienced | All Patients | SOF RBV 24 wk. vs PEG RBV 48 wk | 2 | $108,643.85 | 9097.03; 208,190.67 |
1 | Tx Experienced | All Patients | SOF PEG RBV 12 wk. vs BOC PEG RBV 48 wk | 1 | $42,691.76 | NA |
1 | Tx Experienced | Without Cirrhosis | SOF PEG RBV 12 wk. vs BOC PEG RBV 48 wk | 1 | $20,556.36 | NA |
1 | Tx Experienced | All Patients | SOF PEG RBV 12 wk. vs No Tx | 1 | $16,636.38 | NA |
1 | Tx Naïve | All Patients | SOF PEG RBV 12 wk. vs No Tx | 1 | $6183.71 | NA |
1 | Tx Naïve | With Cirrhosis | SOF PEG RBV 12 wk. vs No Tx | 1 | $17,319.03 | NA |
1 | Tx Naïve | Without Cirrhosis | SOF PEG RBV 12 wk. vs No Tx | 1 | $2075.11 | NA |
1 | Tx Experienced | Without Cirrhosis | SOF PEG RBV 12 wk. vs PEG RBV 48 wk | 1 | $28,230.10 | NA |
1 | Tx Naïve | Without Cirrhosis | SOF PEG RBV 12 wk. vs PEG RBV 48 wk | 1 | $27,395.56 | NA |
1 | Tx Experienced | All Patients | SOF PEG RBV 12 wk. vs TEL PEG RBV 48 wk | 1 | $81,887.61 | NA |
1 | Tx Experienced | With Cirrhosis | SOF PEG RBV 12 wk. vs TEL PEG RBV 48 wk | 1 | $30,799.23 | NA |
1 | Tx Experienced | Without Cirrhosis | SOF PEG RBV 12 wk. vs TEL PEG RBV 48 wk | 1 | $22,125.61 | NA |
1 | Tx Naïve | With Cirrhosis | SOF PEG RBV 12 wk. vs TEL PEG RBV 48 wk | 1 | $24,022.23 | NA |
1 | Tx Naïve | Without Cirrhosis | SOF RBV 24 wk. vs No Tx | 1 | $74,046.69 | NA |
1 | Tx Naïve | All Patients | SOF RBV 24 wk. vs PEG RBV 48 wk | 1 | $203,337.60 | NA |
2 | Tx Naïve | With Cirrhosis | SOF PEG RBV 12 wk. vs PEG RBV 24 wk | 1 | $36,118.69 | NA |
2 | Tx Naïve | Without Cirrhosis | SOF PEG RBV 12 wk. vs PEG RBV 24 wk | 1 | $242,147.86 | NA |
2 | Tx Experienced | Without Cirrhosis | SOF RBV 12 wk. vs No Tx | 1 | $64,437.10 | NA |
2 | Tx Naïve | Without Cirrhosis | SOF RBV 12 wk. vs PEG RBV 24 wk | 1 | $89,048.45 | NA |
2 | Tx Experienced | With Cirrhosis | SOF RBV 12 wk. vs PEG RBV 48 wk | 1 | $18,783.93 | NA |
3 | Tx Experienced | With Cirrhosis | SOF PEG RBV 12 wk. vs No Tx | 1 | $12,001.35 | NA |
3 | Tx Experienced | With Cirrhosis | SOF PEG RBV 12 wk. vs PEG RBV 48 wk | 1 | $3389.07 | NA |
3 | Tx Experienced | Without Cirrhosis | SOF PEG RBV 12 wk. vs PEG RBV 48 wk | 1 | $19,301.90 | NA |
3 | Tx Experienced | With Cirrhosis | SOF RBV 12 wk. vs No Tx | 1 | $75,409.37 | NA |
3 | Tx Experienced | Without Cirrhosis | SOF RBV 12 wk. vs No Tx | 1 | $186,528.47 | NA |
3 | Tx Naïve | With Cirrhosis | SOF RBV 12 wk. vs No Tx | 1 | $39,799.39 | NA |
3 | Tx Naïve | Without Cirrhosis | SOF RBV 12 wk. vs No Tx | 1 | $58,784.73 | NA |
3 | Tx Naïve | With Cirrhosis | SOF RBV 12 wk. vs PEG RBV 24 wk | 1 | $189,241.61 | NA |
3 | Tx Experienced | With Cirrhosis | SOF RBV 24 wk. vs PEG RBV 48 wk | 1 | $70,111.60 | NA |
3 | Tx Experienced | Without Cirrhosis | SOF RBV 24 wk. vs PEG RBV 48 wk | 1 | $58,828.37 | NA |